A Phase III open-label randomized study to compare the efficacy of lenalidomide-rituximab with bendamustine-rituximab in treatment-naïve follicular lymphoma.
Sushant Kumar PaikarayAjay GogiaLalit KumarAtul SharmaAhit Agni BiswasVishnubhatla SreenivasSoumya MallickPublished in: Indian journal of cancer (2024)
The ORR was similar in both the arms; however, the CR rate was significantly higher in the BR arm. BR was better tolerated than LR.(CTRI/2016/05/006904).